Back to Results
First PageMeta Content
Catecholamines / Combination drugs / Neurotransmitters / Stalevo / Nitrobenzenes / Carbidopa / Entacapone / Aromatic L-amino acid decarboxylase inhibitor / L-DOPA / Chemistry / Pharmacology / Medicine


B.C. Ministry of Health Services Drug Coverage Decision About PharmaCare  PharmaCare  Coverage  Inside 
Add to Reading List

Document Date: 2014-03-05 12:02:56

Open Document

File Size: 103,19 KB

Share Result on Facebook

Company

Novartis Pharmaceuticals Canada Inc. / Novartis Pharmaceuticals Inc. / /

Event

FDA Phase / Product Issues / /

IndustryTerm

individual products / literature search / products / entacapone combination product / chemical called dopamine / treatment of idiopathic Parkinson’s disease / /

MedicalCondition

tremor / dyskinesias / Parkinson’s Disease / idiopathic Parkinson’s disease / /

Organization

Ministry of Health Services / B.C. Ministry of Health Services Drug Coverage Decision About PharmaCare PharmaCare Coverage Inside B.C. PharmaCare / Pharmaceutical Services Division / Ministry of Health Services Decision / Drug Benefit Council / B.C. Ministry of Health Services Page / PharmaCare / Special Authority / B.C. Ministry of Health Services Drug Coverage Decision Levodopa-carbidopa-entacapone / /

Position

physician / Governor / /

Product

Stalevo / response / /

ProvinceOrState

British Columbia / /

URL

www.health.gov.bc.ca/pharmacare / www.health.gov.bc.ca/pharmacare/formulary / /

SocialTag